Ontology highlight
ABSTRACT: Background
Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL.Materials and methods
We retrospectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity were assessed.Results
The median age at diagnosis was 50.5 years. All patients had extranodal disease; 2 were positive for human immunodeficiency virus. Seven patients received hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone)-based chemotherapy, 2 received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and 1 received dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Radiotherapy (RT) was administered after a complete response to chemotherapy in 7 patients and a partial response in 1 patient. At a median follow-up period of 42 months, the estimated 2-year progression-free and overall survival rates were 90% and 100%, respectively.Conclusion
PBL can be successfully treated with aggressive chemotherapy followed by RT. The treatment was well tolerated and can result in long-term survival for patients with limited-stage disease.
SUBMITTER: Pinnix CC
PROVIDER: S-EPMC9754636 | biostudies-literature | 2016 Mar
REPOSITORIES: biostudies-literature
Pinnix Chelsea C CC Shah Jatin J JJ Chuang Hubert H Costelloe Colleen M CM Medeiros L Jeffrey LJ Wogan Christine F CF Reed Valerie V Smith Grace L GL Milgrom Sarah S Patel Krina K Huo Jinhai J Turturro Francesco F Romaguera Jorge J Fayad Luis L Oki Yasuhiro Y Fanale Michelle A MA Westin Jason J Nastoupil Loretta L Hagemeister Fredrick B FB Rodriguez Alma A Qazilbash Muzaffar M Shah Nina N Bashir Qaiser Q Ahmed Sairah S Nieto Yago Y Hosing Chitra C Rohren Eric E Dabaja Bouthaina B
Clinical lymphoma, myeloma & leukemia 20151222 3
<h4>Background</h4>Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL.<h4>Materials and methods</h4>We retrospectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity ...[more]